Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 4/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.45 |
| ▸ | CDK1 | P06493 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22184356 | 0.87 | PDK2 (0.52) | PDK2KDM1AHRH4MGLLEPHX1 | |
| SCHEMBL14392680 | 0.87 | PDK2 (0.52) | PDK2KDM1AHRH4MGLLEPHX1 | |
| SCHEMBL14924420 | 0.87 | KDM1A (0.63) | PDK2KDM1AHRH4MGLLCDK1 | |
| SCHEMBL22859014 | 0.85 | POLB (0.54) | PDK2KDM1AHRH4MGLLEPHX1 | |
| SCHEMBL1447790 | 0.85 | MGLL (0.50) | KDM1AMGLLEPHX1L3MBTL3CDK1 | |
| SCHEMBL2132882 | 0.85 | EPHX1 (0.63) | PDK2KDM1AHRH4EPHX1L3MBTL3 | |
| SCHEMBL2132888 | 0.85 | EPHX1 (0.63) | PDK2KDM1AHRH4EPHX1L3MBTL3 | |
| SCHEMBL7881494 | 0.85 | EPHX1 (0.63) | PDK2KDM1AHRH4EPHX1L3MBTL3 | |
| SCHEMBL1447944 | 0.83 | MGLL (0.48) | MGLLEPHX1L3MBTL3L3MBTL1EPHX2 | |
| SCHEMBL1447941 | 0.83 | MGLL (0.48) | MGLLEPHX1L3MBTL3L3MBTL1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301928-A1 | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders | AstraZeneca AB (SE) | 2011-03-30 | — | — | EP | disclosed |
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | CCNI, MKI67, TYMP | PDK2 244/4885KDM1A 3180/4885HRH4 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.